The always energetic Petros Grivas gives a rapid overview of the fast paced progress in UC Miami Cancer Institute Research Precision Onc Symposim organized by Manmeet Ahluwalia, MD, MBA, FASCO Rachna Shroff, MD, FASCO Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Bladder Cancer Advocacy Network

Come see our MD Anderson Cancer Center Society of Urologic Oncology #OncSurgery fellows presenting #BladderCancer research at #AUA24

Valentina Grajales MD, MS Amanda Myers Wei Shen Tan Alexis Steinmetz Côme Tholomier Alberto Martini

🔥⬇️ Pls make sure to check the work of our terrific #UroOnc fellows of MD Anderson Cancer Center (@AmandaMyersMD Wei Shen Tan Valentina Grajales MD, MS Côme Tholomier) at Amer. Urol. Assn. #AUA24 !
Happy for rewarding collaboration in #BladderCancer topics w/ unmet needs; mentorship of Omar Alhalabi, MD & Ashish M. Kamat, MD, MBBS!

Particularly like my lanyard this year Kidney Cancer

Very nice to see. Message to AI / ML folks: 'Evaluating ... a model [means] estimating model discrimination (eg, c statistic), model calibration (eg, calibration plot, calibration slope), and clinical utility (eg, decision curve analysis).'

Star studded UTSW Simmons Cancer Center MD Anderson Cancer Center panel for advanced #bladdercancer led by Suzanne Cole, MD, including Omar Alhalabi, MD #MeghanHeberton Matt Campbell MD, MS Neil Desai #AmishiShah
#UTCGW24

Excellent discussion on a tremendous body of work for trimodality therapy for #bladdercancer & approach to bladder preservation. Thanks #DrJasonEfstathiou Mass General Cancer Center for coming to Austin for our #UTCGW24 conference!

🔥Great way to start our final day of #UTCGW24 with our Distinguished Radiology Oncologist Lecture with #DrJasonEfstathiou highlighting his and his team’s great work in trimodality bladder preservation strategy in MIBC.

Leaving a conference session completely outside your interest.

Relevant in GU oncology clinical research too.

👍 Great session on NMIBC moderated by yair lotan. Nice debate with #RobSvatek and Harris Zhaid. Field is moving quickly. Appreciate the great talks by Ashish Kamat Ashish M. Kamat, MD, MBBS and #ColinDinney . Second Annual UTCGW meeting

💥Excited to launch the 2nd Annual UT Christopher G Wood Advances in Urologic Oncology in Austin. In honor of a legend in the field, great friend and mentor to many. Thank you to all speakers, sponsors, and organizing committee to make this a huge success

Omar Alhalabi, MD Matt Galsky Tom Powles Andrea Apolo, M.D. BTW, pretty impressed with how well the above table summarizes RCT data by properly emphasizing comparative metrics. Immediate high yield overview with only some additional refinement needed. Keep it up!

👇Important investigator-initiated work for patients with #AdrenalCancer . Congratulations on seeing this hard work to the finish line! #RareCancers

🔥 HOT OFF THE PRESS: Happy to share the results of *two* Phase 2 studies of cabozantinib in #AdrenalCancer in The Lancet Oncology from MD Anderson Cancer Center

Scroll down for more details ⬇️ #GUSM #GUOncology

Dr Contieri Roberto Contieri presenting our collaborative work at #EAU24 showing that IBCG IR NMIBC system predicts delayed TURBT in patients under active surveillance

empowering informed decision-making and enhanced patient counseling

MD Anderson Cancer Center #OncSurgery

Subsequent treatment of control arm of adjuvant trials is causing controversy due to subsequent IO access. In the +ve renal & bladder studies 81%/48% and ~62%/~36% received further therapy/IO respectively.However the figure below shows these analysis are time dependant & complex

Omar Alhalabi, MD Matt Galsky Tom Powles Andrea Apolo, M.D. Excellent opportunity to take advantage of this medrxiv.org/content/10.110… and use the associated free webtool to help extract signal from noise: alexandersherry.shinyapps.io/shinyapp/ This will help distinguish “no difference” from noise and guide future steps and trials.

#EAU24 #checkmate274 +ve DFS early +ve OS #IM010 -ve for both. #AMBASSADOR +ve DFS early -ve OS. Perhaps too early. How do we explain. Subsequent therapy hard to read. dynamic. Maybe ctDNA+ trials will have clearer signals from more likely events.

Just Out at #AACR24 🇺🇸
Study reveals promising strides in combating clear cell renal cell carcinoma (ccRCC) using cutting-edge CAR T-cell therapy.

✅CTX130, a novel CAR T-cell product targeting CD70, showcased impressive preclinical efficacy, achieving disease control in 81.3%